2850-LB: Perceptions about Once-Weekly Basal Insulin among Insulin-Naïve People with Type 2 Diabetes and Psychological Insulin Resistance
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-2850-lb ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von WILLIAM POLONSKY und 8 weiteren Autor:innen.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction and Objective: Psychological insulin resistance (PIR) delays timely basal insulin initiation in people with type 2 diabetes (PwT2D), contributing to suboptimal glycemic control and increased diabetes-related distress. This study examined perceptions of once-weekly insulin and its potential to reduce PIR among insulin-naïve PwT2D with PIR.
Methods
A cross-sectional online 2026 survey enrolled 146 adult, U.S. PwT2D who were prescribed or recommended basal insulin but never started it in the prior 3 years. All participants had been diagnosed with T2D for ≥1 year and used at least 1 non-insulin diabetes medication in the past 90 days. Measures included injection preferences, willingness to initiate insulin, and attitudes toward weekly insulin.
Results
Respondents were mostly male (75%) with mean (SD) age 46.1 (9.6) years, mean BMI when first recommended to start insulin 29.8 kg/m2 (8.2), and mean Type 2 Diabetes Distress Assessment System (T2-DDAS) Core scale score 3.2 (0.1). Mean time since first being recommended by an HCP to start insulin was 18.2 (9.6) months. Among all respondents, 81% “agreed” or “strongly agreed” that weekly insulin would make them more comfortable starting treatment, 83% reported that it would make insulin management less time-consuming and stressful, and 79% each expected it would support better overall health, help them continue activities they enjoy, and lead a more flexible lifestyle. The majority of respondents (57%) reported they would prefer weekly injections if available, while 36% reported preferring daily and 7% had no preference. Of those preferring weekly, 92% reported willingness to start insulin sooner if a weekly option were available, primarily driven by the possibility of fewer injections (83%).
Conclusion
Among insulin-naïve PwT2D with PIR, once-weekly basal insulin was perceived as a meaningful facilitator of earlier insulin initiation, primarily due to reduced injection burden and stress around insulin management. Disclosure W. Polonsky: Consultant; Current; Vertex Pharmaceuticals Incorporated, Dexcom, Inc., Abbott Diabetes. Research Support; Current; Abbott Diabetes, Dexcom, Inc. Consultant; Current; Lilly Diabetes, MannKind Corporation. Research Support; Current; Lilly Diabetes. Consultant; Current; Sanofi, Insulet Corporation. U. Desai: Other - I am an employee of Analysis Group, Inc. a consulting firm that has received funding from multiple life sciences companies over the last 24 months to conduct research projects.; Current; N/A (see “Other” field). F. Gelsey: Employee; Current; Eli Lilly and Company. Stock/Shareholder; Current; Eli Lilly and Company. R. Ghanbariamin: Other - I am an employee of Analysis Group, Inc., a consulting firm that has received funding from multiple life sciences companies over the last 24 months to conduct research projects.; Current; N/A (see “Other” field). W. da Costa Jr: Other - I am an employee of Analysis Group, Inc., a consulting firm that has received funding from multiple life sciences companies over the last 24 months to conduct research projects.; Current; Not applicable (see “Other” field). J. Chen: Other - I am an employee of Analysis Group, Inc., a consulting firm that has received funding from multiple life sciences companies over the last 24 months to conduct research projects.; Current; N/A (see"Other" field). C. Pham: Other - I am an employee of Analysis Group, Inc., a consulting firm that has received funding from multiple life sciences companies over the last 24 months to conduct research projects.; Current; N/A (see “Other” field). M.B. Davidson: Employee; Current; Eli Lilly and Company. Stock/Shareholder; Current; Eli Lilly and Company. D. Schapiro: Employee; Current; Eli Lilly and Company. Stock/Shareholder; Current; Eli Lilly and Company. Funding Eli Lilly and Company (NA)
Zitieren
APA
POLONSKY, W., DESAI, U., GELSEY, F., GHANBARIAMIN, R., COSTA, W. L. D., CHEN, J., PHAM, C., DAVIDSON, M. B., & SCHAPIRO, D. (2026). 2850-LB: Perceptions about Once-Weekly Basal Insulin among Insulin-Naïve People with Type 2 Diabetes and Psychological Insulin Resistance. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2850-lb
Vancouver
POLONSKY W, DESAI U, GELSEY F, GHANBARIAMIN R, COSTA WLD, CHEN J, et al. 2850-LB: Perceptions about Once-Weekly Basal Insulin among Insulin-Naïve People with Type 2 Diabetes and Psychological Insulin Resistance. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2850-lb
BibTeX
@article{POLONSKY2026,
author = {POLONSKY, WILLIAM and DESAI, URVI and GELSEY, FELICIA and GHANBARIAMIN, ROKSANA and COSTA, WILSON L DA and CHEN, JINGYI and PHAM, CHI and DAVIDSON, MICHAEL B. and SCHAPIRO, DAVID},
title = {2850-LB: Perceptions about Once-Weekly Basal Insulin among Insulin-Naïve People with Type 2 Diabetes and Psychological Insulin Resistance},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-2850-lb}
}
EUVIMED